Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
STAT Asks a Question Many Patients Already Live With
A recent piece from STAT, titled "When symptoms persist despite oral antidepressants: What's next for treatment-resistant depression?" (published July 27, 2026), takes on a question that a large share of depression patients eventually face: what happens when the standard first-line medications don't work. STAT is a health and medicine news outlet that covers clinical research and treatment trends, and this report frames the gap between what oral antidepressants can offer and what patients need when those drugs fail to bring relief. You can read the original article on Google News via STAT.
The specific details of STAT's reporting, which experts they interviewed, which data they cite, aren't available to us beyond the headline and framing, so we won't speculate on those specifics. What we can offer is context on what "treatment-resistant depression" (TRD) means clinically, why it's common enough to warrant ongoing coverage, and what the established next-line options look like for someone in this situation, including how ketamine-based treatment fits into that picture.
What "Treatment-Resistant" Actually Means
Clinicians generally use the term treatment-resistant depression when a patient's symptoms haven't adequately improved after trying two or more antidepressants, at adequate doses and for an adequate duration, typically six to eight weeks each. This isn't a rare edge case. A meaningful share of people prescribed a first-line SSRI or SNRI don't reach full remission, and many need to try a second or third medication before finding one that helps, if one does at all. That's the population STAT's headline is speaking to: patients who have already been patient, already followed the standard protocol, and are still symptomatic.
Once someone reaches that point, the standard next steps in psychiatry generally fall into a few categories: switching to a different antidepressant class, adding an augmentation agent such as an atypical antipsychotic or lithium, referring for structured psychotherapy, or moving to a device- or infusion-based treatment such as transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or ketamine/esketamine therapy. Each of these has a different risk profile, cost structure, and evidence base, and a psychiatrist typically weighs them based on prior treatment history, symptom severity, and whether suicidal ideation is present.
Compare your options
Move from the guide into a side-by-side comparison when you are ready to evaluate tradeoffs.
Compare optionsKey Takeaway
If you've tried two or more antidepressants without adequate relief, that experience meets the clinical threshold many providers use for treatment-resistant depression. It's a signal to talk with a prescriber about next-line options, including ketamine or esketamine therapy, rather than simply waiting longer on the same medication.
Where Ketamine and Esketamine Fit for TRD Patients
Within this landscape, ketamine-based treatments occupy a specific and increasingly well-documented niche. Esketamine (brand name Spravato) received FDA approval in 2019 specifically for treatment-resistant depression in adults who have not responded to at least two oral antidepressants, and it's administered as a nasal spray under medical supervision, typically alongside a continued oral antidepressant. Intravenous or intramuscular ketamine for depression is used off-label, meaning it's prescribed based on a clinician's judgment and supporting research rather than an FDA-approved indication for that specific route, and it's typically offered through specialty clinics rather than a standard psychiatry practice. Both approaches differ from traditional antidepressants in mechanism and speed: many patients and clinicians report symptom changes within hours to days rather than the weeks typical of SSRIs, though individual response varies and isn't guaranteed.
Coverage like STAT's matters for our readers because it reflects a broader shift in how psychiatry frames the TRD conversation. For years, the default advice for a non-responding patient was simply to try another pill. Increasingly, the field is treating device- and infusion-based options as legitimate next steps to raise earlier in the conversation, not as treatments of last resort. That shift has real implications for access, insurance coverage, and how quickly a patient with persistent symptoms can move toward something that might actually work for them.
Practical Steps If You're Considering Ketamine Therapy
For readers evaluating whether ketamine or esketamine therapy might be the right next step, a few practical points are worth keeping in mind. First, document your treatment history clearly, including which medications you've tried, at what doses, and for how long, since this history is what a clinic or prescriber will use to determine whether you meet the criteria for treatment-resistant depression. Second, ask any clinic you're considering how they screen for medical and psychiatric contraindications, such as uncontrolled hypertension or a history of psychosis, and what their follow-up protocol looks like after a session, since ongoing monitoring and integration with your existing mental health care matter as much as the treatment itself. Third, clarify costs and coverage up front. Esketamine is FDA-approved and may have a clearer path to insurance coverage than off-label IV ketamine, which is frequently an out-of-pocket expense; ask any provider directly rather than assuming coverage. Finally, treat ketamine therapy as one option among several rather than a guaranteed fix. Response rates vary, and a reputable provider should be transparent about that uncertainty rather than promising a specific outcome.
The broader takeaway from continued mainstream coverage of TRD, including reporting like STAT's, is that patients no longer need to feel stuck when standard antidepressants haven't worked. The evidence base and the range of legitimate next-line treatments have both grown, and asking a provider directly about ketamine, esketamine, TMS, or ECT is a reasonable and increasingly common step, not an unusual one.
Share
Related Reading
Have a question about this topic?
Use the contact page when you need to send feedback, request a correction, or ask about the resource.